FMR LLC - 26 Oct 2021 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Other*
Signature
Kevin M. Meagher, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Issuer symbol
XLO
Transactions as of
26 Oct 2021
Net transactions value
$0
Form type
4
Filing time
28 Oct 2021, 15:45:21 UTC
Previous filing
21 Oct 2021
Next filing
12 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XLO Common Stock Conversion of derivative security +789,473 +3000% 815,788 26 Oct 2021 F-Prime Capital Partners Healthcare Fund IV LP F1
transaction XLO Common Stock Conversion of derivative security +686,499 +84% 1,502,287 26 Oct 2021 F-Prime Capital Partners Healthcare Fund IV LP F1
transaction XLO Common Stock Conversion of derivative security +28,703 +1.9% 1,530,990 26 Oct 2021 F-Prime Capital Partners Healthcare Fund IV LP F1
transaction XLO Common Stock Conversion of derivative security +372,215 372,215 26 Oct 2021 Impresa Fund III Limited Partnership F1
transaction XLO Common Stock Conversion of derivative security +4,465 4,465 26 Oct 2021 F-Prime Capital Partners Healthcare Advisors Fund IV LP F1
holding XLO Common Stock 26,315 26 Oct 2021 F-Prime Capital Partners Healthcare Fund IV LP

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Series A Preferred Stock Conversion of derivative security -7,500,000 -100% 0 26 Oct 2021 Common Stock 789,473 F-Prime Capital Partners Healthcare Fund IV LP F1
transaction XLO Series A-1 Preferred Stock Conversion of derivative security -6,521,739 -100% 0 26 Oct 2021 Common Stock 686,499 F-Prime Capital Partners Healthcare Fund IV LP F1
transaction XLO Series B Preferred Stock Conversion of derivative security -272,687 -100% 0 26 Oct 2021 Common Stock 28,703 F-Prime Capital Partners Healthcare Fund IV LP F1
transaction XLO Series B Preferred Stock Conversion of derivative security -3,536,046 -100% 0 26 Oct 2021 Common Stock 372,215 Impresa Fund III Limited Partnership F1
transaction XLO Series B Preferred Stock Conversion of derivative security -42,421 -100% 0 26 Oct 2021 Common Stock 4,465 F-Prime Capital Partners Healthcare Advisors Fund IV LP F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

FMR LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Healthcare Advisors Fund IV LP (FPCPHA) is the general partner of F-Prime Capital Partners Healthcare Fund IV LP. FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.